Avalon GloboCare Corp. (NASDAQ:ALBT) Sees Significant Increase in Short Interest

Avalon GloboCare Corp. (NASDAQ:ALBT) saw a large increase in short interest in September. As of September 15th, there was short interest totalling 300,700 shares, an increase of 35.7% from the August 31st total of 221,600 shares. Approximately 5.1% of the shares of the stock are sold short. Based on an average daily volume of 4,430,000 shares, the days-to-cover ratio is currently 0.1 days.

Avalon GloboCare Stock Performance

Shares of NASDAQ ALBT opened at $0.22 on Friday. The stock has a market capitalization of $2.43 million, a P/E ratio of -0.16 and a beta of 0.31. The stock’s fifty day moving average is $0.30 and its 200 day moving average is $0.35. Avalon GloboCare has a 52 week low of $0.19 and a 52 week high of $1.44.

Avalon GloboCare (NASDAQ:ALBT) last released its earnings results on Monday, August 19th. The company reported ($0.19) EPS for the quarter. The business had revenue of $0.33 million for the quarter.

Avalon GloboCare Company Profile

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells.